Literature DB >> 30108764

Synthesis and biological evaluation of 8-hydroxy-2,7-naphthyridin-2-ium salts as novel inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE).

M Schiedel1, A Fallarero2, C Luise3, W Sippl3, P Vuorela2, M Jung1.   

Abstract

By analogy with the natural product chelerythrine, which has been identified as an inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), we prepared a small series of 8-hydroxy-2,7-naphthyridin-2-ium salts. Spectroscopic analyses allowed us to elucidate the zwitterionic nature of 2,7-naphthyridin-1(7H)-ones, the neutral state of 8-hydroxy-2,7-naphthyridin-2-ium salts. Among the tested compounds, we identified dual inhibitors of AChE and BChE as well as an inhibitor showing a preferential inhibition of AChE over BChE. By in vitro characterization in combination with docking studies, we were able to identify structural features that influence the biological activity of 8-hydroxy-2,7-naphthyridin-2-ium salts.

Entities:  

Year:  2017        PMID: 30108764      PMCID: PMC6072306          DOI: 10.1039/c6md00647g

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  39 in total

1.  Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs.

Authors:  G Kryger; I Silman; J L Sussman
Journal:  Structure       Date:  1999-03-15       Impact factor: 5.006

2.  Galantamine-based hybrid molecules with acetylcholinesterase, butyrylcholinesterase and γ-secretase inhibition activities.

Authors:  L Vezenkov; J Sevalle; D Danalev; T Ivanov; A Bakalova; M Georgieva; F Checler
Journal:  Curr Alzheimer Res       Date:  2012-06       Impact factor: 3.498

3.  Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent.

Authors:  Nigel H Greig; Tadanobu Utsuki; Donald K Ingram; Yue Wang; Giancarlo Pepeu; Carla Scali; Qian-Sheng Yu; Jacek Mamczarz; Harold W Holloway; Tony Giordano; DeMao Chen; Katsutoshi Furukawa; Kumar Sambamurti; Arnold Brossi; Debomoy K Lahiri
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-07       Impact factor: 11.205

4.  Identification and characterization of diarylimidazoles as hybrid inhibitors of butyrylcholinesterase and amyloid beta fibril formation.

Authors:  Daniela Karlsson; Adyary Fallarero; Gerda Brunhofer; Przemyslaw Guzik; Michaela Prinz; Ulrike Holzgrabe; Thomas Erker; Pia Vuorela
Journal:  Eur J Pharm Sci       Date:  2011-11-16       Impact factor: 4.384

Review 5.  Alzheimer's disease: a disorder of cortical cholinergic innervation.

Authors:  J T Coyle; D L Price; M R DeLong
Journal:  Science       Date:  1983-03-11       Impact factor: 47.728

Review 6.  Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease.

Authors:  D Muñoz-Torrero
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

7.  A step toward the reactivation of aged cholinesterases--crystal structure of ligands binding to aged human butyrylcholinesterase.

Authors:  Marielle Wandhammer; Martijn de Koning; Marco van Grol; Mélanie Loiodice; Laura Saurel; Daan Noort; Maurice Goeldner; Florian Nachon
Journal:  Chem Biol Interact       Date:  2012-08-16       Impact factor: 5.192

8.  Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective butyrylcholinesterase inhibitor.

Authors:  Ciaran G Carolan; Gerald P Dillon; Denise Khan; Sheila A Ryder; Joanne M Gaynor; Sean Reidy; Juan F Marquez; Mike Jones; Valerie Holland; John F Gilmer
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

9.  A fluorometric assay of SIRT1 deacetylation activity through quantification of nicotinamide adenine dinucleotide.

Authors:  Yu Feng; Jiahui Wu; Lei Chen; Chen Luo; Xu Shen; Kaixian Chen; Hualiang Jiang; Dongxiang Liu
Journal:  Anal Biochem       Date:  2009-08-13       Impact factor: 3.365

Review 10.  Cholinesterase inhibitors: new roles and therapeutic alternatives.

Authors:  Ezio Giacobini
Journal:  Pharmacol Res       Date:  2004-10       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.